Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

Abstract: Germicidal lamp apparatuses are provided with lamps disposed between upper and lower bases of a support structure. In some embodiments, a longitudinal axis of a lamp is at an acute angle greater than 0° relative to a region of the lower base between the lamp and another lamp. In addition, the longitudinal axis of the other lamp is at either a right angle or an obtuse angle relative to said region. Other embodiments of apparatuses include a reflector system disposed between the upper and lower bases which is common to the lamps and which includes a reflector with slanted peripheral edge. Other germicidal lamp apparatuses are provided which include a reflector with multiple sections each contoured to manipulate directionality of light emitted from a subset of lamps. In such cases, the apparatuses are configured to move the reflector and/or collectively move the lamps during illumination of the lamps.

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: A system and method for providing end user speech applications. The system is embodied in an application environment framework which exchanges messages with a target execution platform having a local call flow interpreter. A speech application comprised of a plurality of generic call flow objects is executed on the application environment framework. While the speech application executes, the application environment framework translates the generic call flow objects into platform specific call flow objects having a format recognizable by the local call flow interpreter of the target execution platform, formats the platform specific call flow objects into reply messages using a protocol recognizable by the target execution platform, and transmits the messages to the target execution platform. In this manner, a platform independent speech application effectively controls the operation of a platform dependent call flow interpreter to provide voice interaction with an end user.